Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Noninterventional Extension Study for Patients Treated in Study R5459-RT-1944 With Vonsetamig (BCMA x CD3 Bispecific Antibody) Who Receive a Kidney Transplant

NCT05106387 is registered in ClinicalTrials.gov with Regeneron Pharmaceuticals as lead sponsor.

NCT NCT05106387
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05106387 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Noninterventional Extension Study for Patients Treated in Study R5459-RT-1944 With Vonsetamig (BCMA x CD3 Bispecific Antibody) Who Receive a Kidney Transplant
Lead sponsor
Regeneron Pharmaceuticals
Phase
Observational
Overall status
Recruiting
Start date
October 19, 2023
Completion date
February 23, 2028
Enrollment
20 (estimated)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

chronic kidney disease (ckd)